Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Myeloid Leukemia, BCR/ABL Studies and Myeloproliferative Disorders

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL

Leukemia volume 20, pages 664–670 (2006)Cite this article

Abstract

Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to therapy in chronic myeloid leukaemia (CML). We wanted to determine in what circumstances additional clinically relevant information was provided by simultaneous cytogenetic analysis in RQ-PCR monitored patients receiving imatinib treatment. We analysed 828 simultaneous RQ-PCR and bone marrow cytogenetic analyses from 183 patients with chronic phase CML with a median follow-up of 20 months. Cytogenetic progression was defined as Philadelphia (Ph)-positive clonal evolution, loss of complete cytogenetic response or an increase of ⩾20% Ph-positive cells. Cytogenetic progression occurred in 24/183 (13%) patients. At the time of cytogenetic progression, none of the 24 patients had a major molecular response (MMR;⩾3-log reduction in BCR-ABL from standardised baseline). There were 320 RQ-PCR results from 95 patients indicating MMR. No abnormality was detected in any of the corresponding cytogenetic analyses. A policy of regular RQ-PCR monitoring with cytogenetic analysis targetted only to patients who have not achieved, or have lost MMR would represent a rational approach to monitoring and spare most patients the discomfort of multiple marrow aspirates. This approach depends upon availability of an accurate, reproducible RQ-PCR assay with ongoing quality assurance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Daley GQ, Van Etten RA, Baltimore D . Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830.

    Article  CAS  Google Scholar 

  2. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N . Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990; 87: 6649–6653.

    Article  CAS  Google Scholar 

  3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566.

    Article  CAS  Google Scholar 

  4. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

    Article  CAS  Google Scholar 

  5. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.

    Article  CAS  Google Scholar 

  6. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472–3475.

    Article  CAS  Google Scholar 

  7. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276–283.

    Article  CAS  Google Scholar 

  8. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125.

    Article  CAS  Google Scholar 

  9. Hochhaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163.

    Article  CAS  Google Scholar 

  10. Branford S, Hughes TP, Rudzki Z . Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107: 587–599.

    Article  CAS  Google Scholar 

  11. Wang L, Pearson K, Ferguson JE, Clark RE . The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 2003; 120: 990–999.

    Article  CAS  Google Scholar 

  12. Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 16: 1579–1583.

    Article  CAS  Google Scholar 

  13. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.

    Article  CAS  Google Scholar 

  14. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003; 9: 160–166.

    CAS  PubMed  Google Scholar 

  15. Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica 2004; 89: 49–57.

    CAS  PubMed  Google Scholar 

  16. Muller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia 2003; 17: 2392–2400.

    Article  CAS  Google Scholar 

  17. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549–1555.

    CAS  PubMed  Google Scholar 

  18. Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003; 17: 2401–2409.

    Article  CAS  Google Scholar 

  19. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–2878.

    Article  CAS  Google Scholar 

  20. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937.

    Article  CAS  Google Scholar 

  21. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J et al. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002; 8: 2167–2176.

    CAS  PubMed  Google Scholar 

  22. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003; 101: 3794–3800.

    Article  CAS  Google Scholar 

  23. O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002; 100: 1628–1633.

    Article  CAS  Google Scholar 

  24. Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM . Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 1996; 14: 196–203.

    Article  CAS  Google Scholar 

  25. Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003; 98: 1905–1911.

    Article  CAS  Google Scholar 

  26. Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004; 18: 1340–1346.

    Article  CAS  Google Scholar 

  27. Bumm T, Muller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941–1949.

    Article  CAS  Google Scholar 

  28. Alimena G, Breccia M, Mancini M, Ferranti G, De Felice L, Gallucci C et al. Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome. Leukemia 2004; 18: 361–362.

    Article  CAS  Google Scholar 

  29. Chee YL, Vickers MA, Stevenson D, Holyoake TL, Culligan DJ . Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia 2003; 17: 634–635.

    Article  CAS  Google Scholar 

  30. Eikelboom JW . RE: Bain BJ. (2004) Bone marrow biopsy morbidity and mortality: 2002 data. Clinical and Laboratory Haematology 26: 315–318. Clin Lab Haematol 2005; 27: 209–210.

    Article  CAS  Google Scholar 

  31. Bain BJ . Bone marrow biopsy morbidity and mortality: 2002 data. Clin Lab Haematol 2004; 26: 315–318.

    Article  CAS  Google Scholar 

  32. . National Pathology Accreditation Advisory Council Guidelines for Cytogenetic Laboratories. Australian Government Department of Health and Ageing: Canberra, 2001.

  33. Mitelman F (ed). An International System for Human Cytogenetic Nomenclature. Karger: Basel, 1995.

    Google Scholar 

  34. Branford S, Hughes TP In: Iland HJ, Hertzberg M, Marlton P (eds). Myeloid Leukemia: Methods and Protocols, Methods in Molecular Medicine. Humana Press: Totawa, NJ, 2005.

    Google Scholar 

  35. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926–2932.

    Article  CAS  Google Scholar 

  36. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE . Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118: 771–777.

    Article  CAS  Google Scholar 

  37. Wiktor A, Rybicki BA, Piao ZS, Shurafa M, Barthel B, Maeda K et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 2000; 27: 11–16.

    Article  CAS  Google Scholar 

  38. United Kingdom Cancer Cytogenetics Group (UKCCG). Loss of the Y chromosome from normal and neoplastic bone marrows. Genes Chromosomes Cancer 1992; 5: 83–88.

    Article  Google Scholar 

  39. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS . Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002; 99: 3129–3135.

    Article  CAS  Google Scholar 

  40. Maserati E, Aprili F, Vinante F, Locatelli F, Amendola G, Zatterale A et al. Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15–20% of cases. Genes Chromosomes Cancer 2002; 33: 93–97.

    Article  CAS  Google Scholar 

  41. Najfeld V, Montella L, Scalise A, Fruchtman S . Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 2002; 119: 558–566.

    Article  Google Scholar 

  42. Paulsson K, Sall T, Fioretos T, Mitelman F, Johansson B . The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Genet Cytogenet 2001; 130: 160–165.

    Article  CAS  Google Scholar 

  43. Fayad L, Kantarjian H, O'Brien S, Seong D, Albitar M, Keating M et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 1997; 11: 767–771.

    Article  CAS  Google Scholar 

  44. Casali M, Truglio F, Milone G, Di Raimondo F, Parrinello G, Maserati E et al. Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia. Genes Chromosomes Cancer 1992; 4: 269–270.

    Article  CAS  Google Scholar 

  45. Hando JC, Nath J, Tucker JD . Sex chromosomes, micronuclei and aging in women. Chromosoma 1994; 103: 186–192.

    Article  CAS  Google Scholar 

  46. Surralles J, Jeppesen P, Morrison H, Natarajan AT . Analysis of loss of inactive X chromosomes in interphase cells. Am J Hum Genet 1996; 59: 1091–1096.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Hanson L, Bryman I, Barrenas ML, Janson PO, Wahlstrom J, Albertsson-Wikland K et al. Genetic analysis of mosaicism in 53 women with Turner syndrome. Hereditas 2001; 134: 153–159.

    Article  CAS  Google Scholar 

  48. Takeshita A, Shinjo K, Yamashita M, Fujisawa S, Naito K, Ohnishi K et al. Extensive cytogenetic studies of clonality following interferon-alpha therapy in chronic myeloid leukemia occurring in monosomic cells in a patient with Turner syndrome mosaic. Leukemia 1999; 13: 1749–1753.

    Article  CAS  Google Scholar 

  49. Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002; 100: 435–441.

    Article  CAS  Google Scholar 

  50. McNamara C, Grigg A, Szer J, Roberts A, Campbell L, Hoyt R et al. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. Clin Lab Haematol 2003; 25: 119–125.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr J Reynolds, Professor P Browett and other members of the Australasian Leukaemia and Lymphoma Group and Drs K Lynch and I Gathmann of Novartis Pharmaceuticals for their assistance in providing data from clinical trial patients.

Author information

Authors and Affiliations

  1. Division of Haematology, Institute of Medical & Veterinary Science, Adelaide, Australia

    D M Ross & T P Hughes

  2. Division of Molecular Pathology, Institute of Medical & Veterinary Science, Adelaide, Australia

    S Branford & S Moore

Authors
  1. D M Ross
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Branford
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T P Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D M Ross.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ross, D., Branford, S., Moore, S. et al. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia 20, 664–670 (2006). https://doi.org/10.1038/sj.leu.2404139

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404139

Keywords

This article is cited by

Search

Advanced search

Quick links